Literature DB >> 27083318

Apelin/APJ system and cancer.

Yanjie Yang1, Shuang-Yu Lv2, Wenling Ye1, Liang Zhang3.   

Abstract

Apelin is an endogenous ligand of the apelin receptor (APJ), a seven-transmembrane G protein-coupled receptor. Apelin/APJ system has a wide tissue distribution in the brain as well as in peripheral organs including heart, lung, vessels, and adipose tissue. Apelin/APJ was involved in regulating cardiac and vascular function, heart development, and vascular smooth muscle cell proliferation. In this article, we summarize the role of apelin/APJ system on lung cancer, gastroesophageal and colonic cancer, hepatocellular carcinoma, prostate cancer, endometrial cancer, oral squamous cell carcinoma, brain cancer, and tumor neoangiogenesis. Apelin/APJ may be a potential anticancer therapeutic target.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APJ; Apelin; Cancer; Carcinoma; Vessels

Mesh:

Substances:

Year:  2016        PMID: 27083318     DOI: 10.1016/j.cca.2016.04.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  23 in total

1.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

2.  Elucidating the impact of cottonseed hydrolysates on CHO cell culture performance through transcriptomic analysis.

Authors:  Swetha Kumar; Venkata Gayatri Dhara; Linda D Orzolek; Haiping Hao; Abbie J More; Eduardo Catchon Lau; Michael J Betenbaugh
Journal:  Appl Microbiol Biotechnol       Date:  2020-11-17       Impact factor: 4.813

3.  Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.

Authors:  Deepika Neelakantan; Samrita Dogra; Bharat Devapatla; Pharavee Jaiprasart; Marie Claire Mukashyaka; Ralf Janknecht; Shailendra Kumar Dhar Dwivedi; Resham Bhattacharya; Sanam Husain; Kai Ding; Sukyung Woo
Journal:  Mol Cancer Res       Date:  2019-03-11       Impact factor: 5.852

4.  Contribution of Apelin-17 to Collateral Circulation Following Cerebral Ischemic Stroke.

Authors:  Wan Jiang; Wei Hu; Li Ye; Yanghua Tian; Ren Zhao; Juan Du; Bing Shen; Kai Wang
Journal:  Transl Stroke Res       Date:  2018-06-18       Impact factor: 6.829

Review 5.  From apelin to exercise: emerging therapies for management of hypertension in pregnancy.

Authors:  Jeffrey S Gilbert
Journal:  Hypertens Res       Date:  2017-04-06       Impact factor: 3.872

6.  Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators.

Authors:  Kleinberg X Fernandez; Conrad Fischer; Jennie Vu; Mahmoud Gheblawi; Wang Wang; Samantha Gottschalk; Xavier Iturrioz; Catherine Llorens-Cortés; Gavin Y Oudit; John C Vederas
Journal:  RSC Med Chem       Date:  2021-07-08

7.  SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.

Authors:  ShuYan Liu; Xiao Li; ZhaoMin Lin; Le Su; Shan Yan; BaoXiang Zhao; JunYing Miao
Journal:  Cancer Lett       Date:  2017-12-13       Impact factor: 8.679

8.  Apelin-13 inhibits apoptosis and excessive autophagy in cerebral ischemia/reperfusion injury.

Authors:  Zi-Qi Shao; Shan-Shan Dou; Jun-Ge Zhu; Hui-Qing Wang; Chun-Mei Wang; Bao-Hua Cheng; Bo Bai
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

Review 9.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 10.  Apelin/APJ system: A key therapeutic target for liver disease.

Authors:  Shuang-Yu Lv; Binbin Cui; Wei-Dong Chen; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.